Treatment Protocol

Immediate-release PGB and PER are established as effective to reduce seizure frequency

Immediate-release PGB and PER are established as effective to reduce seizure frequency

Lacosamide, eslicarbazepine, and extended-release topiramate use should also be considered to decrease seizure frequency

Lacosamide, eslicarbazepine, and extended-release topiramate use should also be considered to decrease seizure frequency

Lacosamide, eslicarbazepine, and extended-release topiramate use should also be considered to decrease seizure frequency

VGB and RFN should be considered established as effective for decreasing seizure frequency in TRAFE but are not first-line agents (retinopathy risk with VGB and modest benefit with RFN).

VGB and RFN should be considered established as effective for decreasing seizure frequency in TRAFE but are not first-line agents (retinopathy risk with VGB and modest benefit with RFN).

Ezogabine use should be considered to decrease seizure frequency in this population but carries a serious risk of skin and retinal discoloration.

Clobazam and OXC-XR use may be considered to decrease seizure frequency in TRAFE

Clobazam and OXC-XR use may be considered to decrease seizure frequency in TRAFE

Eslicarbazepine use may be considered to decrease seizure frequency as monotherapy for TRAFE

Data are insufficient to recommend the use of second- and the other third-generation AEDs as monotherapy in TRAFE

For add-on therapy for GE, immediate-release and LTG-XR use should be considered as add-on therapy to decrease seizure frequency in treating adults with TR GTC seizures secondary to GE

Levetiracetam use should be considered to decrease seizure frequency as add-on therapy for TR GTC seizures and for TR JME

For LGS, RFN use should be considered established as effective to decrease seizure frequency as add-on therapy

And CLB use should be considered